Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
December 27, 2016
RegMed Investors’ (RMi) closing bell analysis, pricing moves were executed in minutes
December 23, 2016
RegMed Investors’ (RMi) closing bell analysis, the last full trading week of the year
December 22, 2016
RegMed Investors’ (RMi) closing bell analysis, no pricing presents under sector’s tree
December 21, 2016
RegMed Investors’ (RMi) closing bell analysis, the sector’s hole gets deeper
December 15, 2016
RegMed Investors’ (RMi) closing bell analysis, the fear and greed indicator is up
December 5, 2016
RegMed Investors’ (RMi) closing bell analysis, let’s keep this upside moving further
December 2, 2016
RegMed Investors’ (RMi) closing bell analysis, lordy, lordy up above
November 29, 2016
RegMed Investors’ (RMi) closing bell analysis, the stem, cell, gene and regenerative therapy (SCG&RT) sector muddles on …
November 28, 2016
RegMed Investors’ (RMi) closing bell analysis, our universe was cruising for a bruising
November 23, 2016
RegMed Investors’ (RMi) closing bell analysis, be thankful …
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.